Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CDX-301 |
Synonyms | |
Therapy Description |
Mobista (CDX-301) is a recombinant Flt3 ligand that binds to and activates the Flt3 receptor, potentially leading to proliferation of immune precursor cells (PMID: 25915810). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-301 | Mobista|CDX 301|CDX301 | Mobista (CDX-301) is a recombinant Flt3 ligand that binds to and activates the Flt3 receptor, potentially leading to proliferation of immune precursor cells (PMID: 25915810). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02129075 | Phase II | NeoVax melanoma vaccine CDX-301 Rasdegafusp alfa | CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma | Completed | USA | 0 |
NCT03804944 | Phase II | CDX-301 CDX-301 + Pembrolizumab Pembrolizumab | Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV) | Recruiting | USA | 0 |